|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
������ |
|
��֢���� |
| ��������������� | |
|
������ |
|
���� |
| PubMed | |
|
Article by |
|
Article by |
������������о���չ
������, ����
�й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о��� �Ͼ� 210042
��10������,���Ժ�������ȫ����ķ����ʲ�������,��Ҫ������������,�����Ƕ�ͯ����ɹ��,Ƥ�������Լ��������й�.�ò����Գ̶Ƚϸ�,����ת��,Ŀǰ�����Ʒ����Բ�����.���������ŷ�������ѧ�ķ�չ�ͻ��̼����ij���,������������о��кܴ��Ծ,Ϊ���������������������������ṩ��һ����Ҫ�ֶ�.������Ҫ��Ŀǰ�ĺ�������������ͺ��ٴ����鷽���������.
[2] Morton DL,Foshag LJ,Hoon DS,et al.Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.Ann Surg,1992,216(4):463-482.
[3] Mitchell MS,Harel W,Groshen S.Association of HLA phenotype with response to active specific immunotherapy of melanoma.J Clin Oncol,1992,10(7):1158-1164.
[4] Berd D,Kairys J,Dunton C,et al.Autologous,hapten-modified vaccine as a treatment for human cancers.Semin Oncol,1998,25(6):646-653.
[5] Jager D,Jager E,Knuth A.Vaccination for malignant melanoma:recent developments.Oncology,2001,60(1):1-7.
[6] Nestle FO,Burg G,Dummer R.New perspectives on immunobiology and immunotherapy of melanoma.Immunol Today,1999,20(1):5-
[7] 7.Coulie PG,Karanikas V,Colau D,et al.A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3.Proc Natl Acad Sci USA,2001,98(18):10290-10295.
[8] Guichard G,Zerbib A,Le Gal FA,et al.Melanoma peptide MART-1(27-35) analogues with enhanced binding capacity to the human class �� histocompatibility molecule HLA-A2 by introduction of a betaamino acid residue:implications for recognition by tumor-infiltrating lymphocytes.J Med Chem,2000,43(20):3803-3808.
[9] Bettinotti MP,Kim CJ,Lee KH,et al.Stringent allele/epitope requirements for MART-1/Melan A immunodominance:implications for peptide-based immunotherapy.J Immunol,1998,161(2):877-889.
[10] Nestle FO,Burg G.Dendritic cells:role in skin diseases and therapeutic applications.Clin Exp Dermatol,1999,24(3):204-207.
[11] Banchereau J,Schuler-Thurner B,Palucka AK,et al.Dendritic cells as vectors for therapy.Cell,2001,.106(3):271-274.
[12] Nestle FO,Banchereau J,Hart D.Dendritic cells:On the move from bench to bedside.Nat Med,2001,7(7):761-765.
[13] Livingston PO,Natoli EJ,Calves MJ,et al.Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.Proc Natl Acad Sci U S A,1987,84(9):2911-2915.
[14] Offringa R,van der Burg SH,Ossendorp F,et al.Design and evaluation of antigen-specific vaccination strategies against cancer.Curr Opin Immunol,2000,12(5):576-582.
[15] Soiffer R,Lynch T,Mihm M,et al.Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma.Proc Natl Acad Sci U S A,1998,95(22):13141-13146.
[16] Schreiber S,Kampgen E,Wagner E,et al.Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells:outcome of a phase �� study.Hum Gene Ther,1999,10(6):983-993.